MNKD
NASD MannKind Corporation$3.31 ↓ -0.03 (-0.96%) Trading Down from the previous close of $3.34, $0.07 below the day’s high of $3.38
- YTD change
- -41.66%
- vs 20-day SMA
- -10.57%
- vs 200-day SMA
- -17.79%
Price ranges
Price & Performance
+0.98 (+41.35%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 56.6% away from all-time highs of $7.63
- MNKD is down 42% since the beginning of the year
- MNKD is down 39% over the past 12 months
- MNKD is down 16% over the past 1 month
- 10% of all MNKD investors are betting against MNKD
MNKD reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -37.8%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- -5.48%
- vs 8-day SMA
- -3.52%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.